What is the share price of Kwality Pharmaceuticals Ltd (KPL) today?
The share price of KPL as on 5th December 2025 is ₹900.10. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Kwality Pharmaceuticals Ltd (KPL) share?
The past returns of Kwality Pharmaceuticals Ltd (KPL) share are- Past 1 week: -3.89%
- Past 1 month: -1.32%
- Past 3 months: -4.50%
- Past 6 months: -4.80%
- Past 1 year: 2.66%
- Past 3 years: 171.59%
- Past 5 years: 1392.83%
What are the peers or stocks similar to Kwality Pharmaceuticals Ltd (KPL)?
The peers or stocks similar to Kwality Pharmaceuticals Ltd (KPL) include:What is the market cap of Kwality Pharmaceuticals Ltd (KPL) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Kwality Pharmaceuticals Ltd (KPL) is ₹929.40 Cr as of 5th December 2025.What is the 52 week high and low of Kwality Pharmaceuticals Ltd (KPL) share?
The 52-week high of Kwality Pharmaceuticals Ltd (KPL) is ₹1235 and the 52-week low is ₹596.05.What is the PE and PB ratio of Kwality Pharmaceuticals Ltd (KPL) stock?
The P/E (price-to-earnings) ratio of Kwality Pharmaceuticals Ltd (KPL) is 23.32. The P/B (price-to-book) ratio is 3.54.Which sector does Kwality Pharmaceuticals Ltd (KPL) belong to?
Kwality Pharmaceuticals Ltd (KPL) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Kwality Pharmaceuticals Ltd (KPL) shares?
You can directly buy Kwality Pharmaceuticals Ltd (KPL) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Kwality Pharmaceuticals Ltd
KPL Share Price
900.100.18% (+1.65)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
KPL Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
KPL Performance & Key Metrics
KPL Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 18.94 | 3.54 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.87 | 5.82 | 0.59% |
KPL Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
KPL Company Profile
Kwality Pharmaceuticals Limited manufactures and exports pharmaceutical formulations for human and veterinary use.
SUNPHARMA
PE Ratio
39.63
39.63
1Y Return
0.45%
0.45%
Buy Reco %
91.67
91.67
TORNTPHARM
PE Ratio
67.04
67.04
1Y Return
12.63%
12.63%
Buy Reco %
76.92
76.92
CIPLA
PE Ratio
23.30
23.30
1Y Return
1.51%
1.51%
Buy Reco %
70.00
70.00
DRREDDY
PE Ratio
18.77
18.77
1Y Return
2.85%
2.85%
Buy Reco %
41.94
41.94
LUPIN
PE Ratio
29.21
29.21
1Y Return
1.24%
1.24%
Buy Reco %
72.22
72.22
KPL Forecast
KPL Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
KPL
KPL
Income
Balance Sheet
Cash Flow
Annual Normal View
KPL Income Statement
KPL Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 99.53 | 138.29 | 166.90 | 142.96 | 263.60 | 459.70 | 253.97 | 309.00 | 372.12 | 425.30 | ||||||||||
Raw Materials | 72.19 | 104.00 | 114.19 | 92.59 | 165.50 | 203.11 | 113.27 | 154.66 | 181.31 | 329.70 | ||||||||||
| Power & Fuel Cost | 2.81 | 2.76 | 3.71 | 4.20 | 6.13 | 11.07 | 12.98 | 17.23 | 23.37 | |||||||||||
| Employee Cost | 3.60 | 4.89 | 7.74 | 10.92 | 14.70 | 18.80 | 28.16 | 30.46 | 41.26 | |||||||||||
| Selling & Administrative Expenses | 8.91 | 11.07 | 13.71 | 19.59 | 41.70 | 48.74 | 32.64 | 30.91 | 37.31 | |||||||||||
| Operating & Other expenses | 1.91 | 3.10 | 11.22 | -2.22 | 5.12 | 2.80 | 19.79 | 14.70 | 6.55 | |||||||||||
EBITDA | 10.11 | 12.47 | 16.33 | 17.88 | 30.45 | 175.18 | 47.13 | 61.04 | 82.32 | 95.60 | ||||||||||
| Depreciation/Amortization | 2.51 | 2.98 | 3.12 | 4.43 | 6.49 | 10.69 | 14.96 | 19.56 | 18.29 | 19.37 | ||||||||||
| PBIT | 7.60 | 9.49 | 13.21 | 13.45 | 23.96 | 164.49 | 32.17 | 41.48 | 64.03 | 76.23 | ||||||||||
| Interest & Other Items | 1.95 | 2.21 | 2.29 | 2.52 | 2.68 | 2.92 | 6.61 | 10.39 | 9.88 | 10.29 | ||||||||||
| PBT | 5.65 | 7.28 | 10.92 | 10.93 | 21.28 | 161.57 | 25.56 | 31.09 | 54.15 | 65.94 | ||||||||||
| Taxes & Other Items | 2.28 | 2.75 | 3.35 | 2.60 | 6.12 | 41.57 | 6.21 | 7.30 | 14.30 | 16.87 | ||||||||||
| Net Income | 3.37 | 4.53 | 7.57 | 8.33 | 15.16 | 120.00 | 19.35 | 23.79 | 39.85 | 49.07 | ||||||||||
| EPS | 2.22 | 4.37 | 7.30 | 8.03 | 14.61 | 115.65 | 18.65 | 22.93 | 38.41 | 47.29 | ||||||||||
| DPS | 0.30 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
KPL Company Updates
KPL Stock Peers
KPL Past Performance & Peer Comparison
KPL Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Kwality Pharmaceuticals Ltd | 23.32 | 3.54 | — |
| Sun Pharmaceutical Industries Ltd | 39.63 | 5.98 | 0.89% |
| Torrent Pharmaceuticals Ltd | 67.04 | 16.88 | 0.85% |
| Cipla Ltd | 23.30 | 3.93 | 1.05% |
KPL Stock Price Comparison
Compare KPL with any stock or ETFCompare KPL with any stock or ETF
KPL
KPL Holdings
KPL Shareholdings
KPL Promoter Holdings Trend
KPL Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
KPL Institutional Holdings Trend
KPL Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
KPL Shareholding Pattern
KPL Shareholding Pattern
KPL Shareholding History
KPL Shareholding History
Foreign Institutions
Mutual Funds Invested in KPL
Mutual Funds Invested in KPL
No mutual funds holding trends are available
Top 1 Mutual Funds holding Kwality Pharmaceuticals Ltd
| Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0006% | Percentage of the fund’s portfolio invested in the stock 0.03% | Change in the portfolio weight of the stock over the last 3 months 0.03% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 113/124 (+1) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing KPL stock
smallcases containing KPL stock
Looks like this stock is not in any smallcase yet.
KPL Events
KPL Events
KPL Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
KPL has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
KPL Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
KPL has not given any dividends in last 5 years
KPL Upcoming Dividends
KPL Upcoming Dividends
No upcoming dividends are available
KPL Past Dividends
KPL Past Dividends
Cash Dividend
Ex DateEx DateJan 5, 2017
Interim
Interim | Div/Share: ₹0.60
Dividend/Share
₹0.60
Ex DateEx Date
Jan 5, 2017
KPL Stock News & Opinions
KPL Stock News & Opinions
Articles & Videos
Earnings
Kwality Pharmaceuticals consolidated net profit rises 66.71% in the September 2025 quarter
Net profit of Kwality Pharmaceuticals rose 66.71% to Rs 14.12 crore in the quarter ended September 2025 as against Rs 8.47 crore during the previous quarter ended September 2024. Sales rose 23.35% to Rs 111.05 crore in the quarter ended September 2025 as against Rs 90.03 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales111.0590.03 23 OPM %22.8321.84 - PBDT23.4117.18 36 PBT18.4512.55 47 NP14.128.47 67 Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Kwality Pharmaceuticals to table results
Kwality Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 November 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Kwality Pharmaceuticals to conduct AGM
Kwality Pharmaceuticals announced that the Annual General Meeting(AGM) of the company will be held on 9 September 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Spotlight
Kwality Pharma secures regulatory approval for anti-cancer drug Bleomycin in Mexico
According to an exchange filing, Bleomycin is a widely used anti-cancer medicine, effective in the treatment of Hodgkin's lymphoma, testicular cancer, and certain squamous cell carcinomas. This approval further strengthens our expansion into highly regulated markets, reinforcing our commitment to delivering quality oncology products globally. The projected business potential is approximately $1 million in the first year, and supplies are expected to commence before the end of Q2 FY26. The company stated that it remains committed to expanding access to high-quality medicines across global markets. Kwality Pharmaceuticals is engaged in the business of manufacturing & trading in pharmaceuticals & allied products. The company's consolidated net profit surged 42.7% to Rs 11.93 crore on 39.2% rise in revenue from operations to Rs 111.48 crore in Q1 FY26 over Q1 FY25. The counter slipped 3.37% to Rs 1,033.05 on the BSE. Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
KPL receives nod to sell its anti-cancer drug Bleomycin 15 IU in Mexico
Kwality Pharmaceutical has received registration for Bleomycin 15 IU in Mexico for sale and distribution. Bleomycin is a widely used anti-cancer medicine, effective in the treatment of Hodgkin's lymphoma, testicular cancer, and certain squamous cell carcinomas. The company said, This approval further strengthens our expansion into highly regulated markets, reinforcing our commitment to delivering quality oncology products globally. The projected business potential is around 1 million USD in the first year, and supplies will commence before the end of Q2FY26Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Kwality Pharmaceuticals consolidated net profit rises 42.70% in the June 2025 quarter
Net profit of Kwality Pharmaceuticals rose 42.70% to Rs 11.93 crore in the quarter ended June 2025 as against Rs 8.36 crore during the previous quarter ended June 2024. Sales rose 39.21% to Rs 111.48 crore in the quarter ended June 2025 as against Rs 80.08 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales111.4880.08 39 OPM %21.6821.65 - PBDT21.7915.14 44 PBT17.0311.12 53 NP11.938.36 43 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Kwality Pharmaceuticals schedules board meeting
Kwality Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 11 August 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Spotlight
Kwality Pharma spurts on strong Q4 numbers
Sequentially, the company's consolidated net profit surged 69.87% while net sales jumped 37.05% in Q4 FY25 over Q3 FY25. Profit before tax and exceptional items stood at Rs 19.07 crore in Q4 FY25, up 45.80% year-on-year and up 67.43% QoQ. The company reported one time expense of Rs 7.09 crore in Q4 March 2024. For the full year, adjusted net profit rose 36.99% to Rs 39.85 crore while net sales increased 20.52% to Rs 370.20 crore in the year ended March 2025 over the year ended March 2024. Profit before tax and exceptional items rose 42% year-on-year to Rs 54.14 crore in FY25 over FY24. The company's net cash from operating activities stood at Rs 52.72 crore in FY25, higher than Rs 42.98 crore in FY24. Kwality Pharmaceuticals is engaged in the business of manufacturing & trading in pharmaceuticals & allied products. Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Kwality Pharmaceuticals consolidated net profit rises 232.34% in the March 2025 quarter
Net profit of Kwality Pharmaceuticals rose 232.34% to Rs 14.49 crore in the quarter ended March 2025 as against Rs 4.36 crore during the previous quarter ended March 2024. Sales rose 25.77% to Rs 115.68 crore in the quarter ended March 2025 as against Rs 91.98 crore during the previous quarter ended March 2024. For the full year,net profit rose 67.44% to Rs 39.85 crore in the year ended March 2025 as against Rs 23.80 crore during the previous year ended March 2024. Sales rose 20.52% to Rs 370.20 crore in the year ended March 2025 as against Rs 307.17 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales115.6891.98 26 370.20307.17 21 OPM %22.3722.43 -21.7221.59 - PBDT24.1618.15 33 72.4357.76 25 PBT19.0713.08 46 54.1438.20 42 NP14.494.36 232 39.8523.80 67 Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Kwality Pharmaceuticals to declare Quarterly Results
Kwality Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 19 May 2025.Powered by Capital Market - Live
7 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 21.09%, vs industry avg of 10.04%
Over the last 5 years, market share increased from 0.06% to 0.09%
Over the last 5 years, net income has grown at a yearly rate of 36.76%, vs industry avg of 20.02%